Ben (L) and Roland Buelow

Hitch­ing a quick ride on the M&A train, As­traZeneca wa­gers $100M cash on T cell en­gager

As­traZeneca has en­gi­neered a $1.27 bil­lion deal to ac­quire a small biotech and its T cell en­gager — with an eye to shak­ing up the stan­dards of care in mul­ti­ple B cell ma­lig­nan­cies.

The deal to snap up TeneoT­wo, which starts with $100 mil­lion up­front, marks the third buy­out that Roland and Ben Buelow have scored un­der the Teneo um­brel­la af­ter sell­ing two oth­er bis­pe­cif­ic com­pa­nies to Ab­b­Vie and Am­gen, re­spec­tive­ly. Just a few weeks ago, the fa­ther-and-son duo raised $60 mil­lion to keep de­vel­op­ing the re­main­ing pro­grams un­der their watch.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.